Thromb Haemost 1997; 77(04): 675-678
DOI: 10.1055/s-0038-1656032
Coagulation
Schattauer GmbH Stuttgart

Decrease in Factor VII Coagulant Activity during Percutaneous Transluminal Coronary Angioplasty by Heparin-Mediated Lipolytic Action

Manjari Mukherjee
1   The Thrombosis Research Institute, Emmanuel Kaye Building, Chelsea, London
,
Michael F Scully
1   The Thrombosis Research Institute, Emmanuel Kaye Building, Chelsea, London
,
Vijay V Kakkar
1   The Thrombosis Research Institute, Emmanuel Kaye Building, Chelsea, London
2   King’s College School of Medicine and Dentistry, London
3   Royal Brompton Hospital, London
,
Helen Philippou
4   Department of Haematology, Charing Cross and Westminster Hospital Medical School, London, UK
,
David A Lane
4   Department of Haematology, Charing Cross and Westminster Hospital Medical School, London, UK
,
David Jewitt
2   King’s College School of Medicine and Dentistry, London
› Author Affiliations
Further Information

Publication History

Received 02 August 1996

Accepted after resubmission 03 December 1996

Publication Date:
11 July 2018 (online)

Preview

Summary

Levels of factor VII coagulant activity (FVII: C) and two-chain factor Vila antigen (FVIIa: Ag) were measured in ten patients before and up to 6 h after receiving a bolus of heparin during percutaneous transluminal coronary angioplasty (PTCA). A significant and sustained post-heparin fall in the level of FVII: C was observed (approximately 30%) without any change in the level of FVIIa: Ag. The level of tissue factor antigen within the circulation remained unchanged. The observed decrease in FVII: C coincided with a significant decrease in triglyceride levels presumably due to lipoprotein and hepatic lipase released by the heparin. These findings appear to demonstrate a lipid (triglyceride) dependence of FVII: C. Thus, heparin may act indirectly as antithrombotic agent by limiting a lipid-dependent activation of the extrinsic pathway of coagulation.